

Cipla Ltd.

Registered Office :
Cipla House
Peninsula Business Park
Ganpatrao Kadam Marg
Lower Parel
Mumbai – 400 013
India

29th May 2014

(1) BSE Ltd
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: 500087

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBERG
Societe Anonyme
11, av de la Porte-Neuve,
L-2227 Luxembourg

Dear Sirs,

Please find enclosed investor presentation dated 29th May, 2014.

Kindly acknowledge the receipt.

Thank you,

Yours faithfully,
For Cipla Limited



Mital Sanghvi
Company Secretary

Encl: as above



Investor Presentation

Q4 FY 14 Earnings Release

29 May 2014

Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, cash flow projections, our exposure to market risks as well as other risks. Cipla Limited does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof."

Financial Performance Summary – Q4 2013-14



	Quarterly Numbers					
	Standalone			Consolidated		
	Actuals (Rs Cr.)	vs Q4 FY 13	vs Q3 FY 14	Actuals (Rs Cr.)	vs Q4 FY 13	vs Q3 FY 14
Revenue	2,287	16.7%	0.3%	2,520	27.3%	-2.4%
EBITDA	358	-12.5%	-11.1%	409	-3.9%	-12.4%
EBITDA %	15.7%	-5.2%	-2.0%	16.2%	-5.3%	-1.9%
PAT	277	3.4%	6.1%	261	-5.7%	-8.3%
PAT %	12.1%	-1.6%	0.7%	10.3%	-3.6%	-0.7%
R&D	125	23.2%	-0.1%	146	43.6%	10.3%
R&D %	5.5%	0.3%	0.0%	5.8%	0.7%	0.7%

Financial Performance Summary – FY 2013-14



	Full Year Numbers			
	<u>Standalone</u>		<u>Consolidated</u>	
	Actuals (Rs Cr.)	vs FY 13	Actuals (Rs Cr.)	vs FY 13
Revenue	9,380	14.4%	10,100	22.0%
EBITDA	1,990	-6.1%	2,133	-2.9%
EBITDA %	21.2%	-4.6%	21.1%	-5.4%
PAT	1,388	-7.9%	1,388	-10.1%
PAT %	14.8%	-3.6%	13.7%	-4.9%
R&D	518	21.7%	545	28.3%
R&D %	5.5%	0.3%	5.4%	0.3%

Summary of Performance


Area	Achievements
Financial Performance	<ul style="list-style-type: none">▪ Ending year 1 of a 2 year investment cycle▪ Robust sales growth (22% vs. previous year); crossed Rs. 10,000 crore mark▪ Strong operating cash flow >60% of operating profit for the year▪ EBITDA on track based on agreed 3 year plan with Board➤ Excluding one off impact of Escitalopram, despite investments in acquisitions, people and R&D pipeline, we were able to make up several margin points through manufacturing cost efficiencies and pricing levers
Strategy	<ul style="list-style-type: none">▪ De-risked critical markets (South Africa, Uganda)▪ 3 year business plan in place to achieve our growth aspiration▪ Africa contributes 25% of overall sales

Summary of Performance

Area	Achievements
R&D/Pipeline	<ul style="list-style-type: none">▪ R&D expense 5.4% of sales for full year (5.8% for Q4, 5.1% for FY 2012-13)▪ New Integrated Product Development structure successfully implemented▪ ~30% increase in efficiency and productivity levels▪ Secured 3 year pipeline, >85% of 2014-15 critical launches on track▪ >200 formulation development projects underway▪ >90 Europe/North America filings for formulations; >1000 International filings▪ >50 Europe/North America approvals; 800+ approvals in other international markets▪ Overall respiratory progress on track – established as a ‘horizontal’ business unit
People	<ul style="list-style-type: none">▪ Built world class leadership team, all key hiring completed▪ New organisation structure implemented (verticals, horizontals and functions)▪ Cipla New Ventures established and completes its first investment
Quality & Safety	<ul style="list-style-type: none">▪ New Quality organisation established - Quality head reports directly to CEO▪ Continuous Improvement to be ahead of cGMP and Regulatory standards

India

Rs. crore




1. Source: IMS

- Significant increase in market share for branded generics – from 4.7% (6 months back) to 5.3%; continue to outpace market growth¹ (16% vs 9% for industry)
- 17% growth in sales for the year
- India business contributed 40% to overall sales – compared to 45% in FY 2012-13
- Share of new product launches increases from 1.5% in Q1, 2012-13 to 3.5% in Q4, 2013-14
- ~15% increase in field force productivity
- Focus on In-licensing opportunities
- Successfully launched Etacept, our first bio-similar for treatment of rheumatoid arthritis

International


Rs. crore



- International business contributed 25% to overall sales (same share last year)
- 30% growth in sales for the year
- 120+ countries, relationship with 180+ partners, range of 1000+ products
- Completed Uganda integration (Key personnel CEO, CFO from Cipla deployed)
- Pan-Africa network of partners offers unique access to the continent; building on our strength in Middle East and APAC
- Well defined, systematic and differentiated market access strategy for each country (Acquire > JV > Partner > Distribution only)
- China, Latin America, Russia strategy build underway
- Global Access established as a horizontal

Cipla Medpro South Africa


Rs. crore



- South Africa business contributed 13.5% to overall sales (on a consolidated basis)
- 26% growth in sales for the year – based on like for like sales
- New CEO on board (Paul Miller with 20+ years pharmaceuticals experience); key personnel from Cipla India deployed (Finance, Manufacturing, Supply Chain)
- Integration completed (Supply chain, Manufacturing, HR and other functions)
- Forex impact due to ZAR depreciation (~Rs. 65 crore for FY 2013-14)
- Acquisition business case on track - leveraging synergies from scale to drive procurement effectiveness and effective cost management

North America


Rs. crore



- North America business contributed 7% to overall sales – compared to 8% in FY 2012-13
- 19% growth in sales for the year
- Expanded pipeline from 35 to >50 products – including several key respiratory products and other complex generics
- 16 filings and 13 approvals in FY 2013-14
- ~ 20 formulation partnerships
- Started team build as we look to go live in Q4 2014-15

Europe

Rs. crore




- Europe business contributed 6% to overall sales – compared to 5.4% in FY 2012-13
- 40% growth in sales for the year
- Established lean front end presence in priority markets
- Focus on respiratory launches

API

API

Rs. crore



- API contributed 7.5% to overall sales – compared to 7% in FY 2012-13
- 29% growth in sales for the year
- Continue to drive cost efficiencies and process improvement initiatives
- 17 DMF filings
- API established as a horizontal

Priorities going forward

1. Clear Focus where we will play to win

- Further strengthen position in home markets (India & South Africa)
- Build front end in select key international markets

2. Successfully launch late stage pipeline

- Focus on Europe respiratory launches
- Explore partnership opportunities

3. Continue to invest in R&D

- Increase filing intensity
- Embed end-to-end Project management
- Continue to enhance efficiency, effectiveness & quality
- Exploit Platform Technologies

4. Disciplined cost management and operational excellence

- Enhance field force productivity
- Drive procurement effectiveness
- Grow costs below revenue

5. Build Organization capability

- Build world class R&D, Regulatory, Quality and General Management capability to enable front end build out
- Establish strong leadership bench and drive capability across the organisation

Drive strong sales + profit growth with right investments in pipeline & capability

- Mid teens topline growth
- Margin levels similar to prior year
- Strong cash flow